New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - danazol 100mg - capsule - 100 mg - active: danazol 100mg excipient: colloidal silicon dioxide gelatin   iron oxide black   lactose lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium laurilsulfate sodium starch glycolate tekprint black sw-9008 titanium dioxide   - endometriosis: danazol is indicated for use in the treatment of endometriosis amenable to hormonal management. menorrhagia: danazol is indicated for the short-term (up to 6 months) management of primary menorrhagia. fibrocystic disease of the breast: danazol is indicated for the treatment of fibrocystic disease of the breast in both pre- and post-menopausal women. hereditary angioedema: danazol is indicated for the prophylaxis of attacks of hereditary angioedema of a severe or life-threatening nature, in male and female patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - danazol 200mg - capsule - 200 mg - active: danazol 200mg excipient: colloidal silicon dioxide erythrosine gelatin   iron oxide red iron oxide yellow lactose lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium laurilsulfate sodium starch glycolate tekprint black sw-9008 titanium dioxide   - endometriosis: danazol is indicated for use in the treatment of endometriosis amenable to hormonal management. menorrhagia: danazol is indicated for the short-term (up to 6 months) management of primary menorrhagia. fibrocystic disease of the breast: danazol is indicated for the treatment of fibrocystic disease of the breast in both pre- and post-menopausal women. hereditary angioedema: danazol is indicated for the prophylaxis of attacks of hereditary angioedema of a severe or life-threatening nature, in male and female patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - flutamide 250mg;   - tablet - 250 mg - active: flutamide 250mg   excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified water sodium laurilsulfate - for the palliative treatment of advanced prostatic cancer in previously untreated patients or those who have not responded or who have become refractory to hormonal manipulation. as a component of the treatment used in the management of locally advanced prostatic carcinoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - cyproterone acetate 2mg;  ;  ; ethinylestradiol 0.035mg;   - film coated tablet - active: cyproterone acetate 2mg     ethinylestradiol 0.035mg   excipient: hypromellose lactose monohydrate magnesium stearate povidone propylene glycol purified talc   quinoline yellow starch titanium dioxide colloidal silicon dioxide hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose propylene glycol purified talc   starch titanium dioxide - androgen-dependent diseases in women are an indication for treatment with ginet. these diseases may include: acne (where local treatment or oral antibiotics alone have not been successful), especially pronounced forms of acne that may be accompanied by inflammation or formation of nodes (acne nodulocystica, acne papulopustulosa), seborrhea, mild forms of hirsutism and/or androgenic alopecia. oral contraception in women requiring treatment for these androgen-dependent diseases is an indication for treatment with ginet. however ginet is not recommended in women solely for contraception. it should not be used in combination with other hormonal contraceptives. ginet is indicated for the relief of symptoms of polycystic ovary syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 11.34mg equivalent to 10.8 mg goserelin;   - injection (depot) - 10.8 mg - active: goserelin acetate 11.34mg equivalent to 10.8 mg goserelin   excipient: polyglactin - zoladex 10.8 mg is indicated for the management of: 1. prostate cancer suitable for hormonal manipulation.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 3.8mg equivalent to 3.6 mg goserelin;   - injection (depot) - 3.6 mg - active: goserelin acetate 3.8mg equivalent to 3.6 mg goserelin   excipient: polyglactin - zoladex 3.6 mg is indicated for the management of: 1. prostate cancer suitable for hormonal manipulation.

Israel - English - Ministry of Health

cts chemical industries ltd, israel - ursodeoxycholic acid - tablets - ursodeoxycholic acid 100 mg - ursodeoxycholic acid - ursodeoxycholic acid - dissolution or reductin in size of radiolucent cholesterol in patient with a functioning gallbladder. treatment of chronic liver diseases including primary billiary cirrhosis, primary sclerosing cholangitis, cystic fibrosis associated liver disease, biliary atresia, chronic hepatitis, and alcohol cirrhosis.

Israel - English - Ministry of Health

cts chemical industries ltd, israel - ursodeoxycholic acid - tablets - ursodeoxycholic acid 300 mg - ursodeoxycholic acid - ursodeoxycholic acid - dissolution or reduction in size of radiolucent cholesterol gallstones in patients with a functioning gallbladder. treatment of chronic liver diseases including primary biliary cirrhosis, primary sclerosing cholangitis, cystic fibrosis associated liver disease, biliary atresia chronic hepatitis and alcoholic cirrhosis.

Israel - English - Ministry of Health

bayer israel ltd - levonorgestrel - intrauterine device - levonorgestrel 52 mg - levonorgestrel and estrogen - levonorgestrel and estrogen - contraception and idiopathic menorrhagia. protection from endometrial hyperplasia during estrogen replacement therapy.

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - desogestrel; ethinylestradiol - tablets - desogestrel 150 mcg; ethinylestradiol 30 mcg - desogestrel and estrogen - desogestrel and estrogen - oral contraceptive.